文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-Pentixafor PET/CT用于华氏巨球蛋白血症/淋巴浆细胞淋巴瘤疗效评估:与18F-FDG PET/CT比较

Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该前瞻性队列研究纳入15例华氏巨球蛋白血症/淋巴浆细胞淋巴瘤(WM/LPL)患者,在基线和治疗后行68Ga-pentixafor与18F-FDG PET/CT,用视觉评估分析PET/CT疗效并与临床疗效比较。基线时68Ga-pentixafor PET/CT全部阳性(15/15),18F-FDG PET/CT阳性11/15;化疗后总缓解率86.7%(13/15)。68Ga-pentixafor PET/CT在疗效评估上优于18F-FDG PET/CT。

要点

  • 基线时68Ga-pentixafor PET/CT对WM/LPL病灶检出阳性率为15/15,高于18F-FDG PET/CT的11/15。
  • 化疗后总缓解率为86.7%(13/15),68Ga-pentixafor PET/CT可显示不同程度的肿瘤缓解。
  • 18F-FDG PET/CT在6/13例中未能检出疾病改善,并在2例进展患者中漏诊1例。

核心结论

  • 在WM/LPL疗效评估中,68Ga-pentixafor PET/CT优于18F-FDG PET/CT。

研究设计与样本

  • 前瞻性队列研究纳入15例WM/LPL患者,在基线和治疗后均行68Ga-pentixafor与18F-FDG PET/CT。
  • 采用视觉评估分析PET/CT疗效,并与临床疗效进行比较。

主要发现

  • 基线时15/15例患者68Ga-pentixafor PET/CT阳性,18F-FDG PET/CT阳性11/15例。
  • 化疗后总缓解率为86.7%(13/15),这些患者68Ga-pentixafor PET/CT较基线显示不同程度的肿瘤缓解。
  • 2例进展患者中,68Ga-pentixafor PET/CT检出新生病灶或肿瘤受累处68Ga-pentixafor摄取显著增高。
  • 18F-FDG PET/CT在6/13例患者中未能检出疾病改善,并在2例进展患者中漏诊1例。

关键数值与推荐

  • 基线68Ga-pentixafor PET/CT阳性15/15例,18F-FDG PET/CT阳性11/15例。
  • 化疗后总缓解率86.7%(13/15)。
  • 18F-FDG PET/CT未检出疾病改善6/13例,漏诊疾病进展1/2例。

临床怎么用

  • 对WM/LPL患者,可考虑使用68Ga-pentixafor PET/CT进行疗效评估,以弥补18F-FDG PET/CT在检出疾病改善和进展方面的不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 68Ga-pentixafor PET/CT was reported to have a high sensitivity in detecting tumor involvement of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in our previous study. We aimed to further investigate its value in response assessment in WM/LPL. PATIENTS AND METHODS: Fifteen patients with WM/LPL were recruited in a prospective cohort study and underwent both 68Ga-pentixafor and 18F-FDG PET/CT at baseline and posttreatment. PET/CT-based responses were analyzed with visual assessments and compared with clinical response. RESULTS: At baseline, all of the 15 patients had a positive 68Ga-pentixafor PET/CT scan, whereas 18F-FDG PET/CT was positive in 11/15 patients. After chemotherapy, the overall response rate was 86.7% (13/15), and 68Ga-pentixafor PET/CT showed different degree of tumor response from baseline in these patients. In the 2 patients with progressive disease, 68Ga-pentixafor PET/CT detected new lesions or remarkable increase of 68Ga-pentixafor uptake in tumor involvements. However, 18F-FDG PET/CT failed to detect the improvement of disease in 6/13 patients and missed disease progression in 1 of the 2 patients. CONCLUSIONS: 68Ga-pentixafor PET/CT outperformed 18F-FDG PET/CT in response assessment of WM/LPL.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pan Q, Cao X, Luo Y, et al. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. Clin Nucl Med. 2021. PMID: 34172595. doi:10.1097/RLU.0000000000003760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。